Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials
Journal of the European Academy of Dermatology and Venereology | Sep 17, 2019
Most read this week